Myriad Genetics Inc reports results for the quarter ended June 30 - Earnings Summary

Myriad Genetics

31/07/2026 07:26

Myriad Genetics Inc MYGN.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 5 cents.  The mean expectation of nine analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -12 cents to 3 cents per share.
Revenue fell 10.5% to $190.70 million from a year ago; analysts expected $206.03 million. 
Myriad Genetics Inc's reported EPS for the quarter was a loss of 46 cents​.
The company reported a quarterly loss of $43.2 million.
Myriad Genetics Inc shares had fallen by 6.0% this quarter and lost 12.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 590.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is  "buy."
Wall Street's median 12-month price target for Myriad Genetics Inc is $6.00, about 10.5% above its last closing price of $5.37
This summary was machine generated from LSEG data July 31 at 06:26 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.06
-0.25
Missed
Mar. 31 2026 
-0.07
-0.09
Missed
Dec. 31 2025 
-0.01
0.04
Beat
Sep. 30 2025 
-0.01
0.00
Beat